Group 1: Market Overview - The Hang Seng Index rose by 1.88%, gaining 470 points to close at 25,439 points, while the Hang Seng Tech Index increased by 2.35% [1] - The early trading volume in the Hong Kong stock market reached HKD 143.8 billion [1] Group 2: Biotechnology Sector - The Hang Seng Biotechnology Index surged by 3.77%, driven by a collective rise in pharmaceutical stocks following the debut of the "dual directory" for drug applications [1] - Zhonghui Biotech-B (02627) saw a significant increase of 24%, while Jiuyuan Gene (02566) rose by 8.99%, and Kintor Pharmaceutical (09939) increased by 5.7% [1] - Innovent Biologics (01801) experienced a rise of 7.27%, and He Yu-B (02256) reached a new high with a 7.38% increase, reporting a 59% year-on-year growth in net profit for the first half of the year [1] Group 3: Pharmaceutical Developments - Daqi Pharmaceutical-B (06996) rose over 15% as Claudin 18.2 ADC was proposed for inclusion as a breakthrough therapy [2] Group 4: Technology Sector - Tencent's subsidiaries reported generally better-than-expected earnings, with Tencent Music-SW (01698) rising by 15%, and Reading Group (00772) also increasing by over 15% [2] - Weimeng Group (02013) saw an increase of over 7% [2] Group 5: Industrial and Manufacturing Sector - Chongqing Machinery (02722) rose by 8.9%, with an expected 50% year-on-year growth in net profit due to rapid growth in AIDC engine demand [3] - Zhongyan Hong Kong (06055) increased by over 7%, maintaining its position in the domestic cigarette export tax-free business, with earnings to be announced next Friday [3] Group 6: Technology and Electronics - Qiu Tai Technology (01478) rose by over 8%, reporting a 167% year-on-year increase in net profit for the first half of the year, leading to target price upgrades from multiple institutions [4] - Hong Teng Precision (06088) increased by over 9% post-earnings, with a cumulative rise of over 60% in the month, reporting an 11% revenue growth but a 3% decline in net profit [5] - Minmetals Resources (01208) rose by over 9% after reporting a 15-fold increase in net profit for the first half of the year and lowering cost guidance for its mines [6] Group 7: Performance Review - 361 Degrees (01361) fell by over 10% post-earnings, with institutions stating that the first half performance met expectations, but net profit growth was slightly lower than revenue growth [7]

Group 1 - Kangji Medical (09997) resumed trading with a nearly 1% increase, announcing a privatization agreement with Knight Bidco Limited, which will make Kangji a wholly-owned subsidiary and delist from the Hong Kong Stock Exchange after completion [1] - Tencent Music (01698) opened high with over a 15% increase, reporting a 30% year-on-year increase in adjusted net profit for Q2 ending June 30, 2025, driven by high-quality growth in its online music business [1] - Mingyuan Cloud (00909) opened over 2% higher, announcing a cash acquisition of 100% equity in ASIOT Co., Ltd. for 700 million yen by its subsidiary MytePro Japan [1] Group 2 - Yuedu Group (00772) surged over 15%, reporting a 68.5% year-on-year increase in net profit for the first half of the year, with strong performance in IP for premium films and animations, and significant growth in the emerging short drama sector [2] - Minmetals Resources (01208) rose over 9%, with net profit increasing 15 times year-on-year, attributed to higher copper production and rising prices of copper, gold, silver, and zinc [2] - Beihai Kangcheng-B (01228) increased over 31%, announcing a strategic cooperation agreement with Baiyang Pharmaceutical for exclusive commercial services in promoting several products in mainland China, Hong Kong, and Macau [2] Group 3 - Zhonghui Biotech-B (02627) surged over 25%, as its vaccine product was included in the preliminary review list of the national commercial health insurance innovative drug catalog [2] - Gilead Sciences-B (01672) rose over 5%, announcing promising efficacy results for its candidate drug ASC47 in combination with teriparatide for obesity treatment in diet-induced obesity mouse studies [3] - Dongying Travel (06882) fell over 9%, issuing a profit warning with expected net profit of approximately 6 million HKD for the first half of 2025, down about 82% from 34 million HKD in the same period last year [3] Group 4 - Kodak (KODK.US) dropped 19.91% after reporting a shift from profit to loss in Q2, raising concerns about its ability to execute critical financing measures [4] - Niu Technologies (NIU.US) rose 11.69%, reporting a turnaround to profitability in Q2 and projecting Q3 revenue between 1.433 billion to 1.638 billion CNY, a year-on-year increase of 40% to 60% [4] - Huya (HUYA.US) increased by 4.53%, preparing to release its financial report, with a strong growth trajectory in gaming-related services [4] Group 5 - ON Running (ONON.US) rose 8.95%, reporting a 32% year-on-year increase in Q2 sales and projecting annual net sales of at least 2.91 billion Swiss francs, exceeding previous expectations [6] - Micron Technology (MU.US) increased by 3.26%, significantly raising its Q4 fiscal year 2025 revenue guidance to between 11.1 billion to 11.3 billion USD, with gross margin guidance improved to 44% to 45% [6]

Core Viewpoint - Zhonghui Biotech-B (02627) has seen its stock price increase over 20%, reaching a new high of 54 HKD, which is three times its IPO price of 12.9 HKD [1] Group 1: Stock Performance - As of the latest update, the stock is up 22.65%, trading at 53.6 HKD with a transaction volume of 43.85 million HKD [1] - The company's total market capitalization has surpassed 21 billion HKD [1] Group 2: Product Development - Zhonghui Biotech announced that its quadrivalent influenza virus subunit vaccine, branded as Huiru Kangs, has been included in the preliminary review list of innovative drugs for national commercial health insurance [1] - The vaccine received New Drug Application (NDA) approval from the National Medical Products Administration of China in May 2023, and it is intended for individuals aged three and above [1] - This vaccine is the first and only quadrivalent influenza virus subunit vaccine approved in China until July 21, 2025 [1]

智通财经APP获悉，中慧生物-B(02627)再涨超20%，高见54港元续创新高，较招股价12.9港元已涨三 倍。截至发稿，涨22.65%，报53.6港元，成交额4385.22万港元，总市值突破210亿港元。 消息面上，中慧生物今早公布，根据国家医疗保障局于8月12日发布的公告，本年度国家商业健康保险 创新药品目录通过初步审查的名单中，包括唯一一款疫苗产品—四价流感病毒亚单位疫苗。集团的商品 名为慧尔康欣的四价流感病毒亚单位疫苗于2023年5月获得中国国家药品监督管理局的新药申请(NDA) 批准，可用于三岁及以上人群(就含病毒株血凝素浓度而言规格为15μg/0.5ml)，为截至2025年7月21日在 中国获批的首款且唯一一款四价流感病毒亚单位疫苗。 ...

Core Viewpoint - The successful IPO of Zhonghui Biotech-B (02627) on August 11, 2025, marked a significant event in the Hong Kong stock market, with the stock price soaring by 157.98% on its first day, setting a record for the highest first-day gain of a new stock in 2025 [1] Company Overview - Zhonghui Biotech is a domestic innovative vaccine company with two core products: the quadrivalent influenza virus subunit vaccine (Huiruankangxin®) and an in-development lyophilized human rabies vaccine [1][2] - The company has seen a substantial increase in valuation, from 746 million yuan to 4.189 billion yuan during its pre-IPO financing rounds, with participation from renowned long-term funds [1] Product Details - Huiruankangxin® is the first and only approved quadrivalent influenza virus subunit vaccine in China, showing a nearly 400% increase in sales revenue from 52.2 million yuan in 2023 to 260 million yuan in 2024 [2] - The rabies vaccine, developed using human diploid cells, is expected to be a safer alternative to traditional Vero cell rabies vaccines, with Phase I clinical trials completed and Phase III trials planned for Q3 2025 [3] Market Potential - The global human vaccine market is projected to grow from $37.2 billion in 2019 to $49.8 billion by 2024, with a compound annual growth rate (CAGR) of 8.0% [5] - The Chinese human vaccine market is expected to grow from 535 billion yuan in 2019 to 961 billion yuan by 2024, with a CAGR of 12.4% [6] Strategic Initiatives - Zhonghui Biotech's fundraising plan includes over 10% of funds allocated for strategic acquisitions, with 63.6% focused on global registration of core products [4] - The company is expanding its international presence, with plans to submit registration applications in multiple countries, including Thailand, Uruguay, and Indonesia [2][4] Industry Context - The rise of innovative drugs in China is evident, with the share of China's innovative drug business development (BD) transactions increasing from 10.8% in 2015 to over 50% in 2023 [3] - The recent policy support from the National Healthcare Security Administration for innovative drugs further enhances the market environment for companies like Zhonghui Biotech [5]

（原标题：中慧生物-B(02627)旗下慧尔康欣®作为唯一疫苗入选国家医保创新药品初审名单） 集团的商品名为慧尔康欣的四价流感病毒亚单位疫苗于2023年5月获得中国国家药品监督管理局的新药 申请(NDA)批准，可用于三岁及以上人群(就含病毒株血凝素浓度而言规格为15μg/0.5ml)，为截至2025 年7月21日在中国获批的首款且唯一一款四价流感病毒亚单位疫苗，旨在针对两种甲型流感病毒(H1N1 和H3N2亚型)和两种乙型流感病毒(Yamagata和Victoria谱系)提供广泛保护。该产品在传统病毒裂解疫苗 的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风险低等优势。 智通财经APP讯，中慧生物-B(02627)发布公告，根据国家医疗保障局于2025年8月12日发布的公告，本 年度国家商业健康保险创新药品目录通过初步审查的名单中，包括唯一一款疫苗产品—四价流感病毒亚 单位疫苗。 ...

Core Viewpoint - Zhonghui Biotech-B (02627.HK) announced that its quadrivalent influenza virus subunit vaccine has been included in the preliminary review list of the national commercial health insurance innovative drug catalog, marking it as the only vaccine product in this year's list [1] Group 1: Product Approval and Features - The quadrivalent influenza virus subunit vaccine, marketed as Huiru Kangsxin, received new drug application (NDA) approval from the National Medical Products Administration of China in May 2023 [1] - This vaccine is approved for individuals aged three and above, with a specification of 15μg/0.5ml for the hemagglutinin concentration of the virus strains [1] - It is the first and only quadrivalent influenza virus subunit vaccine approved in China as of July 21, 2025, targeting two types of influenza A viruses (H1N1 and H3N2 subtypes) and two types of influenza B viruses (Yamagata and Victoria lineages) [1] Group 2: Advantages of the Vaccine - The product represents a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of component antigens, and a lower risk of adverse reactions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 此為本公司刊發的自願公告。不能保證本集團最終能夠成功開發並推廣其四價流 感病毒亞單位疫苗至所有預期適用年齡群體。本公司股東及潛在投資者於買賣本 公司證券時務請審慎行事。 承董事會命 江蘇中慧元通生物科技股份有限公司 執行董事、董事長兼總經理 安有才先生 Ab&B Bio-Tech CO., LTD. JS 江蘇中慧元通生物科技股份有限公司 香港，2025年8月13日 （於中華人民共和國成立的股份有限公司） 於本公告日期，董事會成員包括：(i)執行董事安有才先生、李潤香女士及何一鳴 先生；(ii)非執行董事程千文先生、于建林先生及杜沐先生；及(iii)獨立非執行董 事李向明先生、李曉青女士及陳乘貝先生。 （股份代號：2627) 自願性公告 本公告乃由江蘇中慧元通生物科技股份有限公司（「本公司」，連同其附屬公司「本 集團」）自願刊發，旨在向本公司股東（「股東」）及潛在投資者提供有關本公司最新 發展之資料。 ...

Core Viewpoint - The successful IPO of Zhonghui Biotech-B (02627) on August 11, 2025, marked a significant event in the Hong Kong stock market, with the stock price soaring by 157.98% on its first day, setting a record for the highest first-day gain of a new stock in 2025 [1] Company Overview - Zhonghui Biotech is a domestic innovative vaccine company with two core products: the quadrivalent influenza virus subunit vaccine (brand name: Huiru Kexin) and an in-development lyophilized human rabies vaccine [1][2] - The quadrivalent influenza vaccine is the first and only one approved in China for individuals aged 3 and above, showing significant improvements over traditional vaccines [2] Financial Performance - The public offering phase saw 191,000 participants with an oversubscription rate of 4007 times, freezing over HKD 210 billion, making it the "super subscription king" of the year in the biotech sector [1] - Sales revenue for Huiru Kexin is projected to reach HKD 260 million in 2024, a nearly 400% increase from HKD 52.2 million in 2023 [2] Product Pipeline - In addition to the two core products, Zhonghui Biotech has 11 other vaccines in development, including a trivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine, creating a diverse product pipeline [3] Market Trends - The Chinese innovative drug market is experiencing rapid growth, with the proportion of innovative drug business development (BD) transactions increasing from 10.8% in 2015 to 52.5% by August 2023 [3] - The global human vaccine market is expected to grow from USD 37.2 billion in 2019 to USD 49.8 billion in 2024, with a compound annual growth rate (CAGR) of 8.0% [5] Strategic Initiatives - Zhonghui Biotech's fundraising plan includes over 10% of funds allocated for strategic acquisitions, particularly in Southeast Asia, to enhance local production capabilities [4] - The company is also benefiting from favorable policies supporting innovative drugs, as indicated by recent meetings held by the National Medical Insurance Administration [5] Investment Appeal - The company is viewed as a defensive asset against global uncertainties, with its innovative vaccine technology positioned to thrive amid public health challenges [6] - The Chinese human vaccine market is projected to grow from RMB 53.5 billion in 2019 to RMB 96.1 billion in 2024, indicating substantial market potential [6]

Core Viewpoint - The successful IPO of Zhonghui Biotech-B (02627) on August 11, 2025, marked a significant event in the Hong Kong stock market, with the stock price soaring by 157.98% on its first day, setting a record for the highest first-day gain of a new stock in 2025 [1] Company Overview - Zhonghui Biotech is an innovative vaccine company in China, with two core products: the quadrivalent influenza virus subunit vaccine (Huiruankangxin®) and an in-development lyophilized rabies vaccine [1][3] - The company has seen a substantial increase in valuation from 746 million yuan to 4.189 billion yuan through three rounds of financing prior to its IPO [1] Product Details - Huiruankangxin® is the first and only quadrivalent influenza virus subunit vaccine approved in China, showing a nearly 400% increase in sales revenue from 52.2 million yuan in 2023 to 260 million yuan in 2024 [2] - The rabies vaccine, developed using human diploid cells, is expected to be a safer alternative to traditional Vero cell-based vaccines, with Phase I clinical trials completed and Phase III trials planned for Q3 2025 [3] Market Potential - The global human vaccine market is projected to grow from $37.2 billion in 2019 to $49.8 billion by 2024, with a compound annual growth rate (CAGR) of 8.0% [5] - The Chinese human vaccine market is expected to grow from 535 billion yuan in 2019 to 961 billion yuan by 2024, with a CAGR of 12.4% [6] Strategic Initiatives - Zhonghui Biotech's fundraising plan includes over 10% of funds allocated for strategic acquisitions, with 63.6% focused on global registration of core products [4] - The company is expanding its international presence, with plans to register products in multiple countries, including Thailand, Uruguay, and Indonesia [2][4] Industry Context - The rise of innovative drugs in China is evident, with the share of China's innovative drug business development (BD) transactions increasing from 10.8% in 2015 to over 50% in 2023 [3] - The company is positioned to benefit from favorable policies supporting innovative drugs, as indicated by recent meetings held by the National Healthcare Security Administration [5]